Catheter Precision Raises $3.47M via Private Placement of Preferred Stock

Key Facts

In a move aimed at strengthening liquidity and addressing financial obligations, Catheter Precision announced the closing of a private placement for 3,470 shares of Series C-3 Convertible Preferred Stock. The company successfully raised approximately $3.47 million through this offering, with the preferred stock priced at $1,000 per share. The proceeds are earmarked for working capital, repayment of existing loans, and general corporate purposes.

This capital raise comes at a critical time for micro-cap medical technology firms, where preferred equity remains a common tool for securing cash despite its dilutive impact on existing shareholders. Compared to sector peers, companies facing cash flow constraints often utilize these instruments; for instance, VTAK shares face potential pressure due to a conversion price set at $0.632 with a $0.35 floor, per offering data. This type of financing is particularly sensitive to market volatility and the broader high-interest-rate environment which elevates traditional borrowing costs.

Regarding stock performance, VTAK closed at $0.56 (as of July 14, 2026), sitting near the lower end of its daily range of $0.552 to $0.7177. Investors should monitor the company's ability to improve its balance sheet following debt repayment, while keeping an eye on upcoming US economic data that could shift risk appetite in the healthcare sector, especially given ongoing fluctuations in inflation and employment metrics.